Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
February 9, 2026
Hematology Today—February 9, 2026
February 9, 2026
Oncology Today—February 9, 2026
February 9, 2026
AI in Healthcare and Digital Health Today—February 9, 2026
February 8, 2026
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
February 7, 2026
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
February 6, 2026
Vaccines Video Recap—February 6, 2026
February 6, 2026
Respiratory Video Recap—February 6, 2026
February 6, 2026
Public Health Today—February 6, 2026
February 6, 2026
Vaccines Today—February 6, 2026
February 6, 2026
Respiratory Today—February 6, 2026
February 6, 2026
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
February 5, 2026